We have created a rapidly expanding pre-clinical pipeline consisting of small molecular weight antibiotics for the treatment of MDR Gram-negative bacteria, as well as a novel taxol-derivative for the targeting of various hyporesponsive breast and ovarian cancer cells.
At the core of STM’s innovation lies our highly adaptable molecular transporter platform technology, which facilitates the intelligent repurposing of existing FDA-approved drugs. By capitalising on such off-patent drugs, we instill significant de-risking into all our programs, enabling a safer and speedier development of a rich pipeline, amenable for parenteral and enteral administration.
This includes programs for differentiated medicines to treat serious multidrug-resistant Gram-negative infections, such as ESBL producing E. coli, carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter baumannii (CRAB), azithromycin-resistant Neisseria gonorrhoeae and other types of life-threatening bacterial infections.
AMR is a predictable and insidious pandemic. SuperTrans Medical is committed in providing clinical infectious disease specialists with desperately needed novel antibiotics in consort with appropriate guidelines to treat and cure patients suffering from life-threatening infections caused by urgent threat pathogens. STM-001 is the company’s first revitalised glycopeptide compound for the targeting of E. coli-associated, complicated urinary tract infections.
Dr. Lewis F. Neville, CEO SuperTrans Medical